08:00 AM EDT, 08/25/2025 (MT Newswires) -- BriaCell Therapeutics ( BCTX ) said Monday that it has received a roughly $2 million research grant from the US government's National Cancer Institute to develop its Bria-PROS+ immunotherapy for prostate cancer.

The grant will be used to complete manufacturing of Bria-PROS+ and fund the company's upcoming phase 1/2a study in advanced prostate cancer patients, BriaCell said.